Skip to main content
Clinical Trials/NCT01165931
NCT01165931
Withdrawn
Phase 2

A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease

Bayer0 sitesMay 2012

Overview

Phase
Phase 2
Intervention
Riociguat (BAY63-2521)
Conditions
Coronary Artery Disease
Sponsor
Bayer
Primary Endpoint
The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration
Status
Withdrawn
Last Updated
12 years ago

Overview

Brief Summary

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
January 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Bayer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male and female patients with coronary artery disease

Exclusion Criteria

  • Patents with coronary artery disease with \>/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery \[LAD\], left circumflex coronary artery \[LCX\] or right coronary artery \[RCA\]) undergoing cardiac catheterization

Arms & Interventions

Arm 1

Intervention: Riociguat (BAY63-2521)

Outcomes

Primary Outcomes

The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration

Time Frame: Within 5 min after completion of the intracoronary Riociguat infusion

Secondary Outcomes

  • Adverse event collection(Until 30 days after study drug treatment)

Similar Trials